Randomized clinical trial of single-versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery

2007 ◽  
Vol 94 (6) ◽  
pp. 683-688 ◽  
Author(s):  
Y. Mohri ◽  
H. Tonouchi ◽  
M. Kobayashi ◽  
K. Nakai ◽  
M Kusunoki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Multiple Dose ◽  
Antimicrobial Prophylaxis ◽  
Cancer Surgery ◽  
Gastric Cancer Surgery ◽  
Single Versus

Effect of early oral feeding after gastric cancer surgery: A result of randomized clinical trial

Surgery ◽  
2011 ◽  
Vol 149 (4) ◽  
pp. 561-568 ◽  
Author(s):  
Hoon Hur ◽  
Sung Geun Kim ◽  
Jung Ho Shim ◽  
Kyo Young Song ◽  
Wook Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Surgery ◽  
Oral Feeding ◽  
Gastric Cancer Surgery ◽  
Early Oral Feeding

scholarly journals A Prospective Randomized Study to Assess the Optimal Duration of Intravenous Antimicrobial Prophylaxis in Elective Gastric Cancer Surgery

2012 ◽  
Vol 97 (2) ◽  
pp. 169-176 ◽  
Author(s):  
Norihiro Haga ◽  
Hideyuki Ishida ◽  
Toru Ishiguro ◽  
Kensuke Kumamoto ◽  
Keiichiro Ishibashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Single Dose ◽  
Multiple Dose ◽  
Dose Group ◽  
Antimicrobial Prophylaxis ◽  
Randomized Study ◽  
Surgical Site Infections ◽  
Cancer Surgery ◽  
Site Infection ◽  
Gastric Cancer Surgery

Abstract The duration of antimicrobial prophylaxis in gastric cancer surgery is not yet established. This prospective randomized study was performed to confirm the noninferiority of single-dose versus multiple-dose antimicrobial prophylaxis in terms of the incidence of surgical-site infection in gastric cancer surgery. Three hundred twenty-five patients undergoing elective resection for gastric cancer were randomized to receive only single-dose cefazolin (1 g) during surgery (single-dose group) or an additional 5 doses every 12 hours postoperatively (multiple-dose group). The overall incidence of surgical-site infections was 9.1% in the single-dose group and 6.2% in the multiple-dose group [difference (95% confidence interval): −2.9% (−5.9%–0.0%)]. Multivariate logistic regression analysis identified blood loss, being overweight, and advanced age as significant independent risk factors for surgical-site infection. Single-dose antimicrobial prophylaxis seemed to be acceptable, and choosing multiple-dose prophylaxis may have little impact on the prevention of surgical-site infections in elective gastric cancer surgery.

Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial

2012 ◽  
Vol 12 (5) ◽  
pp. 381-387 ◽  
Author(s):  
Hiroshi Imamura ◽  
Yukinori Kurokawa ◽  
Toshimasa Tsujinaka ◽  
Kentaro Inoue ◽  
Yutaka Kimura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Antimicrobial Prophylaxis ◽  
Cancer Surgery ◽  
Open Label ◽  
Phase 3 ◽  
Gastric Cancer Surgery ◽  
Randomised Controlled

scholarly journals Is 72 h of antimicrobial prophylaxis better than 24 h in elective gastric cancer surgery?

2018 ◽  
Vol 48 (6) ◽  
pp. 1135-1140
Author(s):  
Xiang XIA ◽  
Gang ZHAO ◽  
Wei LING ◽  
Fengrong YU
Keyword(s):  
Gastric Cancer ◽  
Antimicrobial Prophylaxis ◽  
Cancer Surgery ◽  
Gastric Cancer Surgery ◽  
Better Than

scholarly journals Randomized clinical trial of 24 versus 72 h antimicrobial prophylaxis in patients undergoing open total gastrectomy for gastric cancer

2017 ◽  
Vol 104 (2) ◽  
pp. e158-e164 ◽  
Author(s):  
A. Takagane ◽  
Y. Mohri ◽  
T. Konishi ◽  
R. Fukushima ◽  
T. Noie ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Total Gastrectomy ◽  
Antimicrobial Prophylaxis ◽  
Open Total Gastrectomy

scholarly journals Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy: A randomized clinical trial

2020 ◽  
Vol 101 ◽  
pp. 422
Author(s):  
M. Mandro ◽  
A. Dusabimana ◽  
J.N. Siewe Fodjo ◽  
D. Mukendi ◽  
F. Nyisi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Multiple Dose ◽  
Single Versus

A randomized phase III trial to determine the efficacy of postoperative antimicrobial prophylaxis in gastric cancer surgery (OGSG0501)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15576-e15576
Author(s):  
K. Inoue ◽  
H. Imamura ◽  
Y. Kimura ◽  
K. Fujitani ◽  
Y. Miyake ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Site Infection ◽  
Infection Rate ◽  
Distal Gastrectomy ◽  
Antimicrobial Prophylaxis ◽  
Cancer Surgery ◽  
Phase Iii ◽  
Site Infection ◽  
Phase Iii Trial ◽  
Gastric Cancer Surgery

e15576 Background: In Japan, antimicrobial prophylaxis (AMP) is typically administered for 3 to 4 days postoperatively in gastric cancer surgery. This far exceeds the recommended 24h or less laid out by the Centers for Disease Control (CDC) guidelines for the prevention of surgical-site infections, after a clean-contaminated operation. Methods: A multicenter randomized phase III trial was designed to evaluate the effect of postoperative AMP in gastric cancer surgery. Patients (pts) were required to have histologically proven gastric cancer which was curable by distal gastrectomy, be classifiable as ASA 1 or 2, and have adequate organ function. Pts were randomized to: (A) perioperative AMP (cefazolin 1g, at <30min before incision, every 3h intraoperative supplements) plus postoperative AMP (cefazolin 1g, twice daily for 2 postoperative days) or (B) perioperative AMP alone. Pts were stratified by institution and ASA. The primary endpoint was the incidence of surgical site infection (SSI). With 171 pts per arm, this study had 80% power to demonstrate non-inferiority with 5% margin of peri-AMP alone and 0.05 1-sided alpha. Results: 355 patients were recruited (A: 179, B: 176) in 7 centers between June 2005 and December 2007. The surgical-site infection rate was 9.0 percent (16 of 178) for peri-/post AMP and 4.5 percent (8 of 176) for peri-AMP alone, with no significant differences (Fisher's exact test: P=0.14, RR=1.98 [95%CI, 0.89–4.44]), but showing a significant non-inferiority (P<0.001). The remote site infection rate was 3.4 percent (6 of 178) for peri-/post AMP and 5.1 percent (9 of 175) for peri-AMP alone, with no significant differences (P=0.44, RR=0.66 [95%CI, 0.25- 1.70]). Conclusions: This multicenter randomized phase III trial confirms that postoperative AMP is unnecessary in patients undergoing distal gastrectomy for gastric cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document